{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T10:31:29Z","timestamp":1785148289685,"version":"3.55.0"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug and Alcohol Dependence"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.drugalcdep.2024.111118","type":"journal-article","created":{"date-parts":[[2024,2,8]],"date-time":"2024-02-08T11:43:16Z","timestamp":1707392596000},"page":"111118","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["A qualitative study to determine perspectives of clinicians providing telehealth opioid use disorder treatment"],"prefix":"10.1016","volume":"256","author":[{"given":"Barbara","family":"Burke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Clear","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott G.","family":"Weiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drugalcdep.2024.111118_bib1","unstructured":"Ahmad, F.B., Cisewski, J.A., Rossen, L.M., Sutton, P., 2023. Provisional drug overdose death counts. National Center for Health Statistics. Retrieved January 15, 2024, from https:\/\/www.cdc.gov\/nchs\/nvss\/vsrr\/drug-overdose-data.htm"},{"key":"10.1016\/j.drugalcdep.2024.111118_bib2","series-title":"Journal of substance use and addiction treatment","article-title":"Disparities in access to opioid treatment programs and buprenorphine providers by race and ethnicity in the contiguous U.S","author":"Amiri","year":"2023"},{"issue":"4","key":"10.1016\/j.drugalcdep.2024.111118_bib3","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/S0001-2092(06)61688-8","article-title":"Critical incident technique as a qualitative research method","volume":"74","author":"Byrne","year":"2001","journal-title":"AORN J."},{"key":"10.1016\/j.drugalcdep.2024.111118_bib4","unstructured":"Centers for Disease Control and Prevention, 2023. COVID Data Tracker. Retrieved January 15, 2024, from https:\/\/covid.cdc.gov\/covid-data-tracker\/#datatracker-home."},{"issue":"4","key":"10.1016\/j.drugalcdep.2024.111118_bib5","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1037\/h0061470","article-title":"The critical incident technique","volume":"51","author":"Flanagan","year":"1954","journal-title":"Psychol. Bull."},{"issue":"6","key":"10.1016\/j.drugalcdep.2024.111118_bib6","first-page":"761","article-title":"Utilization of Telehealth Solutions for Patients with Opioid Use Disorder Using Buprenorphine: A Scoping Review","volume":"28","author":"Guillen","year":"2022","journal-title":"Telemed. J. e-Health.: Off. J. Am. Telemed. Assoc."},{"issue":"1","key":"10.1016\/j.drugalcdep.2024.111118_bib7","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.52381","article-title":"Telemedicine Use and Quality of Opioid Use Disorder Treatment in the US During the COVID-19 Pandemic","volume":"6","author":"Hailu","year":"2023","journal-title":"JAMA Netw. Open"},{"issue":"10","key":"10.1016\/j.drugalcdep.2024.111118_bib8","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.36914","article-title":"Telemedicine Buprenorphine Initiation and Retention in Opioid Use Disorder Treatment for Medicaid Enrollees","volume":"6","author":"Hammerslag","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.drugalcdep.2024.111118_bib9","series-title":"Quality management in health care, 10.1097\/QMH.0000000000000439","article-title":"Burnout Among Family Physicians in the United States: A Review of the Literature","author":"Hoff","year":"2023"},{"issue":"9","key":"10.1016\/j.drugalcdep.2024.111118_bib10","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1007\/s11606-023-08165-9","article-title":"Long-Term Prospects for Telemedicine in Opioid Use Disorder (OUD) Treatment: Results from a Longitudinal Survey of OUD Clinicians","volume":"38","author":"Huskamp","year":"2023","journal-title":"J. Gen. Intern. Med."},{"issue":"1982","key":"10.1016\/j.drugalcdep.2024.111118_bib11","article-title":"Physicians as shock absorbers: the system of structural factors driving burnout and dissatisfaction in medicine","volume":"337","author":"Jenkins","year":"2023","journal-title":"Soc. Sci. Med."},{"issue":"10","key":"10.1016\/j.drugalcdep.2024.111118_bib12","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1001\/jamapsychiatry.2022.2284","article-title":"Receipt of telehealth services, receipt and retention of medications for opioid use disorder, and medically treated overdose among medicare beneficiaries before and during the COVID-19 pandemic","volume":"79","author":"Jones","year":"2022","journal-title":"JAMA Psychiatry"},{"issue":"5","key":"10.1016\/j.drugalcdep.2024.111118_bib13","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1001\/jamapsychiatry.2023.0310","article-title":"Association of receipt of opioid use disorder-related telehealth services and medications for opioid use disorder with fatal drug overdoses among medicare beneficiaries before and during the COVID-19 Pandemic","volume":"80","author":"Jones","year":"2023","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.drugalcdep.2024.111118_bib14","doi-asserted-by":"crossref","unstructured":"Krawczyk, N., Rivera, B.D., King, C., & Dooling, B.C.E., 2023. Pandemic telehealth flexibilities for buprenorphine treatment: A synthesis of evidence and policy implications for expanding opioid use disorder care in the U.S. medRxiv: the preprint server for health sciences, 2023.03.16.23287373. https:\/\/doi.org\/10.1101\/2023.03.16.23287373","DOI":"10.1101\/2023.03.16.23287373"},{"issue":"10","key":"10.1016\/j.drugalcdep.2024.111118_bib15","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1176\/appi.ajp.21111141","article-title":"Impact of COVID-19 telehealth policy changes on buprenorphine treatment for opioid use disorder","volume":"179","author":"Lin","year":"2022","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.drugalcdep.2024.111118_bib16","series-title":"Telemedicine Journal and e-Health: The Official Journal of the American Telemedicine Association, 10.1089\/tmj.2023.0044","article-title":"Retention in Telehealth Treatment for Opioid Use Disorder Among Rural Populations: A Retrospective Cohort Study","author":"Lira","year":"2023"},{"issue":"2","key":"10.1016\/j.drugalcdep.2024.111118_bib17","doi-asserted-by":"crossref","first-page":"364","DOI":"10.3390\/healthcare10020364","article-title":"The impact of the COVID-19 pandemic on burnout, compassion fatigue, and compassion satisfaction in healthcare personnel: a systematic review of the literature published during the first year of the pandemic","volume":"10","author":"Lluch","year":"2022","journal-title":"Healthcare"},{"key":"10.1016\/j.drugalcdep.2024.111118_bib18","unstructured":"McDermott W.T. United States Drug Enforcement Administration. Letter to DEA Registrants. March 25, 2020. Available at: https:\/\/www.deadiversion.usdoj.gov\/GDP\/(DEA-DC-022)(DEA068)%20DEA%20SAMHSA%20buprenorphine%20telemedicine%20%20(Final)%20+Esign.pdf. Accessed January 15, 2024."},{"issue":"4","key":"10.1016\/j.drugalcdep.2024.111118_bib19","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1177\/109019818801500401","article-title":"An ecological perspective on health promotion programs","volume":"15","author":"McLeroy","year":"1988","journal-title":"Health Educ. Q."},{"issue":"3","key":"10.1016\/j.drugalcdep.2024.111118_bib20","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/JAN.0000000000000419","article-title":"Experiences of opioid use disorder patients receiving buprenorphine through a telehealth program","volume":"32","author":"Moore","year":"2021","journal-title":"J. Addict. Nurs."},{"key":"10.1016\/j.drugalcdep.2024.111118_bib21","article-title":"Full practice authority and burnout among primary care nurse practitioners","volume":"71","author":"O'Connor","year":"2023"},{"issue":"Suppl 3","key":"10.1016\/j.drugalcdep.2024.111118_bib22","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1007\/s11606-023-08120-8","article-title":"Quantifying the digital divide: associations of broadband internet with tele-mental health access before and during the COVID-19 pandemic","volume":"38","author":"O'Shea","year":"2023","journal-title":"J. Gen. Intern. Med."},{"key":"10.1016\/j.drugalcdep.2024.111118_bib23","unstructured":"Prevoznik T.W. United States Drug Enforcement Administration. Letter to DEA Registrants. March 31, 2020. Available at: https:\/\/www.deadiversion.usdoj.gov\/GDP\/(DEA-DC-022)(DEA068)%20DEA%20SAMHSA%20buprenorphine%20telemedicine%20%20(Final)%20+Esign.pdf. Accessed January 15, 2024."},{"issue":"1","key":"10.1016\/j.drugalcdep.2024.111118_bib24","doi-asserted-by":"crossref","first-page":"34","DOI":"10.31486\/toj.22.0101","article-title":"Stop the divide: facilitators and barriers to uptake of digital health interventions among socially disadvantaged populations","volume":"23","author":"Price-Haywood","year":"2023","journal-title":"Ochsner J."},{"key":"10.1016\/j.drugalcdep.2024.111118_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2021.108999","article-title":"Use of telemedicine for opioid use disorder treatment - perceptions and experiences of opioid use disorder clinicians","volume":"228","author":"Riedel","year":"2021","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2024.111118_bib26","article-title":"Evaluation of urine drug screen falsification of results among patients with opioid use disorder receiving treatment in a telehealth model of care","volume":"154","author":"Rollston","year":"2023","journal-title":"J. Subst. Use Addict. Treat."},{"issue":"4","key":"10.1016\/j.drugalcdep.2024.111118_bib27","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.pop.2022.04.002","article-title":"The state of telehealth before and after the COVID-19 pandemic","volume":"49","author":"Shaver","year":"2022","journal-title":"Prim. care"},{"issue":"4","key":"10.1016\/j.drugalcdep.2024.111118_bib28","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.mayocp.2021.09.013","article-title":"Health care expenditures attributable to primary care physician overall and burnout-related turnover: a cross-sectional analysis","volume":"97","author":"Sinsky","year":"2022","journal-title":"Mayo Clin. Proc."},{"issue":"6","key":"10.1016\/j.drugalcdep.2024.111118_bib29","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1097\/ADM.0000000000001006","article-title":"Perspectives of patients receiving telemedicine services for opioid use disorder treatment: a qualitative analysis of user experiences","volume":"16","author":"Sousa","year":"2022","journal-title":"J. Addict. Med."},{"key":"10.1016\/j.drugalcdep.2024.111118_bib30","doi-asserted-by":"crossref","unstructured":"Tierney, A.A., Mosqueda, M., Cesena, G., Frehn, J.L., Pay\u00e1n, D.D., & Rodriguez, H.P., 2023. Telemedicine Implementation for Safety Net Populations: A Systematic Review. Telemedicine journal and e-health: the official journal of the American Telemedicine Association, 10.1089\/tmj.2023.0260. Advance online publication. https:\/\/doi.org\/10.1089\/tmj.2023.0260","DOI":"10.1089\/tmj.2023.0260"},{"key":"10.1016\/j.drugalcdep.2024.111118_bib31","unstructured":"United States Congress. Ryan Haight Online Pharmacy Consumer Protection Act of 2008. Available at: https:\/\/www.congress.gov\/110\/plaws\/publ425\/PLAW-110publ425.pdf. Accessed January 15, 2024."},{"issue":"7","key":"10.1016\/j.drugalcdep.2024.111118_bib32","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1007\/s11606-021-06969-1","article-title":"Telehealth utilization is associated with lower risk of discontinuation of buprenorphine: a retrospective cohort study of US Veterans","volume":"37","author":"Vakkalanka","year":"2022","journal-title":"J. Gen. Intern. Med."},{"issue":"3","key":"10.1016\/j.drugalcdep.2024.111118_bib33","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.2618","article-title":"In-person and telehealth ambulatory contacts and costs in a large us insured cohort before and during the COVID-19 pandemic","volume":"4","author":"Weiner","year":"2021","journal-title":"JAMA Netw. Open"},{"issue":"5","key":"10.1016\/j.drugalcdep.2024.111118_bib34","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.16089","article-title":"Pharmacy availability of buprenorphine for opioid use disorder treatment in the US","volume":"6","author":"Weiner","year":"2023","journal-title":"JAMA Netw. Open"},{"issue":"2","key":"10.1016\/j.drugalcdep.2024.111118_bib35","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1080\/00952990.2023.2180382","article-title":"Telehealth for opioid use disorder: retention as a function of demographics and rurality","volume":"49","author":"Williams","year":"2023","journal-title":"Am. J. Drug Alcohol Abus."},{"issue":"7","key":"10.1016\/j.drugalcdep.2024.111118_bib36","doi-asserted-by":"crossref","DOI":"10.1001\/jamahealthforum.2023.2247","article-title":"Urine drug screening in a telehealth setting for the treatment of opioid use disorder","volume":"4","author":"Williams","year":"2023","journal-title":"JAMA Health Forum"}],"container-title":["Drug and Alcohol Dependence"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871624000395?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871624000395?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T09:32:52Z","timestamp":1759829572000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0376871624000395"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":36,"alternative-id":["S0376871624000395"],"URL":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2024.111118","relation":{},"ISSN":["0376-8716"],"issn-type":[{"value":"0376-8716","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A qualitative study to determine perspectives of clinicians providing telehealth opioid use disorder treatment","name":"articletitle","label":"Article Title"},{"value":"Drug and Alcohol Dependence","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2024.111118","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"111118"}}